by The Mount Sinai Hospital
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.
The … Read more
Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider watching the recording of the OC Education webinar, “But This is Different: Understanding and Getting Support for the Unique Needs of People … Read more
by Lauren Comander
Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is
… Read moreAs presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
— About half of patients responded, duration of response as long as 19 months in three trials
By Charles Bankhead
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more
By Ryan Scott
Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more
Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more
By Kristi Rosa
Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more
Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,
… Read moreA tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already … Read more
By Ashling Wahner
Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more
Clearity’s Perspective: In the January 17, 2024 update to the National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer, several new therapies have been added to the list of acceptable regimens for recurrent platinum-resistant ovarian cancer. For example, trastuzumab deruxtecan … Read more
By James H. Doroshow, M.D.
More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision
… Read moreDespite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.
By Kyle Doherty
Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more
By Rylan DeStefano
An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more
Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) … Read more
Clearity’s Perspective: Cancer cells that have mutations in BRCA or that are HRD-positive are not able to use the so-called homologous recombination repair pathway to fix mistakes in the cancer cell. These cancer cells become reliant on other repair pathways. … Read more
Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.
In an
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
